Sumitomo and Otsuka schizophrenia asset flunks PhIII, companies blame Covid-19 induced placebo effect

Reynald Castañeda

Deputy Editor

Sumitomo and Otsuka’s schizophrenia candidate ulotaront failed its Phase III test, with the companies saying that the Covid-19 pandemic pushed the placebo effect to higher …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sumitomo and Otsuka schizophrenia asset flunks PhIII, companies blame Covid-19 induced placebo effect

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Sum­it­o­mo and Ot­su­ka schiz­o­phre­nia as­set flunks PhI­II, com­pa­nies blame Covid-19 in­duced place­bo ef­fect

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Sumitomo and Otsuka schizophrenia asset flunks PhIII, companies blame Covid-19 induced placebo effect

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

WuXi AppTec will sell cell and gene therapy business to private equity firm

Exclusive: Florida cancer biotech raises $100M Series A

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future